These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Workman P Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933 [TBL] [Abstract][Full Text] [Related]
9. [Antisense targeting in neurology]. Tellería-Díaz A Rev Neurol; 2000 Oct 16-31; 31(8):762-9. PubMed ID: 11082887 [TBL] [Abstract][Full Text] [Related]
10. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591 [TBL] [Abstract][Full Text] [Related]
11. Strategy for the development of novel anticancer drugs. Saijo N; Tamura T; Nishio K Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152 [TBL] [Abstract][Full Text] [Related]
18. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Hoffman RM Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987 [TBL] [Abstract][Full Text] [Related]
19. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective. Perry WL; Weitzman A Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991 [TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]